Physician profile
Jerzy K Magda
NPI 1366433823
$20,758.03
in general payments reported to CMS, 2019-2025
71 companies · $2,996 in 2025
The $2,996 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,796 · 2020: $2,083 · 2021: $3,120 · 2022: $3,068 · 2023: $3,301 · 2024: $3,395 · 2025: $2,996.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,606 · Education: $85.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,605.74 |
| Education | $85.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,937.83 | 2019-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Astrazeneca Pharmaceuticals LP | $2,045.82 | 2019-2025 | Farxiga, Airsupra, Lokelma |
| Abbvie INC. | $1,859.08 | 2019-2025 | |
| Pfizer INC. | $1,578.13 | 2019-2025 | |
| Novo Nordisk INC | $1,445.99 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Janssen Pharmaceuticals, INC | $976.56 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $822.31 | 2019-2024 | Jardiance |
| Merck Sharp & Dohme LLC | $744.03 | 2019-2025 | Verquvo, Gardasil 9, Capvaxive |
| Lilly USA, LLC | $740.03 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $709.00 | 2019-2025 | Repatha, Otezla, Repatha |
| Amarin Pharma, INC. | $663.94 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $404.30 | 2019-2025 | Trintellix |
| Bayer Healthcare Pharmaceuticals INC. | $384.60 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $344.54 | 2020-2025 | |
| Genzyme Corporation | $336.34 | 2019-2021 |
Show all 71 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jerzy Magda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.